Discover why, to improve screening efficiency, it is crucial to identify patients with elevated hepatocellular carcinoma risk ...

New data show that external-beam radiation therapy yielded superior local control and progression-free survival vs TACE in ...

Objective Autophagy participates in the progression of hepatocellular carcinoma (HCC) and the resistance of HCC cells to sorafenib. We investigated the feasibility of sensitising HCC cells to ...

PET-CT imaging with [18F]fluorodeoxyglucose (FDG) and [18F]fluorocholine (FCH) altered treatment plans in only a tiny ...

Tecentriq in combination with bevacizumab will help the 70 or so New Zealanders diagnosed with Hepatocellular Carcinoma (HCC) ...

The treatment of hepatocellular carcinoma (HCC) has made progress due to immune checkpoint inhibitors (ICIs), but still many patients present innate or acquired resistance to ICIs, thus there is a ...

Immune-Onc Therapeutics has dosed the first subject in the Phase Ib/II trial of IO-108 plus Roche’s atezolizumab and ...

New Zealanders now have funded access to a global standard of care treatment for a form of liver cancer, Hepatocellular Carcinoma (HCC), which, unlike many other cancers has a rapidly increasing rate ...

A modeling study predicts a substantial rise in MASLD prevalence and associated liver-related complications in the United ...

The panelist discusses the case of a 60-year-old man diagnosed with unresectable hepatocellular carcinoma (HCC). The patient has a history of metabolic dysfunction-associated steatohepatitis managed ...

Researchers from Medizinische Hochschule Hannover and affiliated organizations reported data from studies aimed to identify non-coding microRNAs (miRNAs) with therapeutic potential against liver ...

SGLT-2 inhibitors vs DPP-4 inhibitors were associated with a reduced risk for liver cirrhosis among patients with type 2 diabetes.